| Name | VII-31 |
| Description | VII-31 is an activator of the NEDDylation pathway, capable of inducing apoptosis in MCF-7, PC-3, and MGC-803 cells. |
| In vitro | Methods: MGC803, MCF-7 and PC-3 cells were treated with VII-31 (0-200 μM, 48 hours), and cell viability was detected by MTT assay.
Results: VII-31 inhibited the cell viability of MGC803, MCF-7 and PC-3 cells, with IC50 values of 0.09±0.01 μM, 0.10±0.006 and 1.15±0.28 μM, respectively. [1] |
| In vivo | Methods: VII-31 (10, 50, 150 mg/kg, subcutaneous injection, 28 days) was used to treat MGC803 cancer cells to establish a subcutaneous transplant tumor model of human gastric cancer. The tumor size was measured with a caliper to study its effect on tumors in mice.
Results: Within 28 days after the first treatment, the tumor volume of mice in the VII-31 treatment group was significantly smaller than that in the control group; the tumor weight of the 50 mg/kg VII-31 treatment group was about 36% lower than that in the control group, and the tumor weight of the 100 mg/kg VII-31 and 150 mg/kg VII-31 treatment groups was 42% and 46% lower than that in the control group, respectively. VII-31 was able to inhibit the progression of tumors in mice and had no obvious toxicity to mice. [1] |
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 5 mg/mL (11.7 mM), Sonication is recommended.
DMSO : 200 mg/mL (467.83 mM), Sonication is recommended.
|
| Inhibitors Related | Stavudine | Aceglutamide | Urea | Tamoxifen | Cysteamine hydrochloride | Metronidazole | Citric Acid Triammonium | Formamide | Dimethyl phthalate | Alginic acid | Sodium Molybdate | Sildenafil citrate |
United States
